Drug Profile
Research programme: beta-lactamase inhibitors - VenatoRx Pharmaceuticals
Alternative Names: VNRX 5119; VNRX-5113; VRNX 5363Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator VenatoRx Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Beta lactamase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Gram-negative infections (Treatment-resistant) in USA (IV) (VenatoRx Pharmaceuticals pipeline, September 2023).
- 13 Sep 2023 Discontinued - Preclinical for Gram-negative infections (Treatment-resistant) in USA (PO) (VenatoRx Pharmaceuticals pipeline, September 2023).
- 28 Jun 2020 No recent reports of development identified for preclinical development in Gram-negative-infections(Treatment-resistant) in USA (IV)